Daratumumab: all 219 studies that test it

Page 1 of 3. Open to participants first (55), then studies with results posted, then the rest; newest registration first within each.

• CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple MyelomaNot yet recruitingNCT07830485Phase 2
• Multi-target Drugs Sequential Combination Therapy in Adults Patients With Newly Diagnosed Primary Immune ThrombocytopeniaRecruitingNCT07788456Phase 4
• Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic LymphomaRecruitingNCT07513129Phase 1
• Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)RecruitingNCT07362238Phase 2
• Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null PhenotypeRecruitingNCT07341867Phase 1
• Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL AmyloidosisRecruitingNCT07335887Phase 2
• Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)RecruitingNCT07297563Phase 2
• The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic AnemiaNot yet recruitingNCT07287228Phase 1/2
• New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies.Not yet recruitingNCT07110662Phase 1/2
• Daratumumab for Late Antibody-Mediated RejectionRecruitingNCT07081126Not applicable
• Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell DisordersRecruitingNCT07075510Phase 1/2
• Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)Not yet recruitingNCT07072585Phase 2/3
• Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP)RecruitingNCT07063199Phase 2
• Daratumumab for Familial Cerebral Cavernous Malformations: A Single-Arm Safety and Efficacy StudyNot yet recruitingNCT07026604Early Phase 1
• Use of a New Medicine "Daratumumab" to Treat Left-over Cancer in a Blood Cancer Called "T Acute Lymphoblastic Leukemia"RecruitingNCT07021677Phase 2
• The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM PatientsNot yet recruitingNCT07015021Not applicable
• A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)RecruitingNCT06953960Phase 1/2
• A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in CombinationsRecruitingNCT06892522Phase 1/2
• The Effect of Daratumumab in Patients With Monoclonal Gammopathy of Renal Significance (MGRS) in FinlandRecruitingNCT06889948Phase 2
• Anti-CD38 Antibody Treating Children With Primary Immune Thrombocytopenia (ITP)RecruitingNCT06838962Phase 2
• Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple MyelomaRecruitingNCT06785415Phase 1/2
• A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple MyelomaRecruitingNCT06768489Phase 1
• Risk Stratification and MRD-driven Maintenance for MM After ASCTRecruitingNCT06697483Not applicable
• An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination With DaratUMumab Followed by Maintenance With Daratumumab in the Frontline Setting of Primary Plasma CEll LRecruitingNCT06636552Phase 2
• Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm StudyRecruitingNCT06455748Not applicable
• Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease DetectionRecruitingNCT06409702Phase 4
• Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell AntibodyRecruitingNCT06358638Phase 2
• 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic SyndromeRecruitingNCT06287944Phase 1
• Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUSRecruitingNCT06189833Phase 2
• FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)RecruitingNCT06187441Phase 3
• Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple MyelomaRecruitingNCT06140966Phase 2
• A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)RecruitingNCT06083922Phase 2
• Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman DiseaseRecruitingNCT05907759Phase 2
• Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA TrialRecruitingNCT05898646Phase 2
• Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple MyelomaRecruitingNCT05896228Phase 2
• ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer InhibitorRecruitingNCT05888870Phase 4
• Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple MyelomaRecruitingNCT05857982Phase 1/2
• Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine or CPX-351) in Patients of 60 Years Old or More With Adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM)RecruitingNCT05749276Phase 1
• Efficacy of Anti-CD20 Ab Associated With Anti-CD38 in the Childhood Multidrug Dependent and Resistant Nephrotic SyndromeRecruitingNCT05704400Phase 2
• Daratumumab in Primary Antiphospholipid SyndromeRecruitingNCT05671757Phase 1/2
• A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for TransplantRecruitingNCT05623020Phase 3
• A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide RefractoryNot yet recruitingNCT05581875Phase 1/2
• Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple MyelomaRecruitingNCT05363111Phase 1
• Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALLRecruitingNCT05289687Phase 2
• A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant IneligibleRecruitingNCT05280275Phase 1/2
• Primary Plasma Cell Leukemia: a Prospective Phase 2 Study Incorporating Daratumumab to Chemotherapy and Stem Cell TransplantationNot yet recruitingNCT05054478Phase 2
• A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other TreatmentsRecruitingNCT05020236Phase 3
• Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)RecruitingNCT04991103Phase 2
• A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaRecruitingNCT04973605Phase 1/2
• Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & LymphomaRecruitingNCT04972942Phase 1
• Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.RecruitingNCT04915248Phase 2
• A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT04910568Phase 1
• A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple MyelomaRecruitingNCT04661137Phase 2
• A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic LymphomaRecruitingNCT04139304Early Phase 1
• Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering MyelomaRecruitingNCT03937635Phase 3
• A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple MyelomaTerminatedNCT05590377Phase 1/2Results posted
• Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple MyelomaActive, not recruitingNCT04756401Phase 2Results posted
• FT538 in Combination With Daratumumab in AML Acute Myeloid LeukemiaCompletedNCT04714372Phase 1Results posted
• A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple MyelomaTerminatedNCT04700176Phase 2Results posted
• Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With DaratumumabTerminatedNCT04407442Phase 2Results posted
• Treatment of POEMS Syndrome With DaratumumabCompletedNCT04396496Phase 2Results posted
• A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to DaratumumabActive, not recruitingNCT04302324Phase 2Results posted
• Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFHTerminatedNCT04251065Phase 2Results posted
• Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT StudyTerminatedNCT04230304Phase 2Results posted
• Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple MyelomaTerminatedNCT04205240Phase 2Results posted
• A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple MyelomaActive, not recruitingNCT04181827Phase 3Results posted
• Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based TherapyActive, not recruitingNCT04140162Phase 2Results posted
• Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple MyelomaActive, not recruitingNCT04113018Phase 2Results posted
• Study of Daratumumab in Patients With Mild to Moderate Alzheimer's DiseaseCompletedNCT04070378Phase 2Results posted
• A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell TransplantCompletedNCT03901963Phase 3Results posted
• INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple MyelomaTerminatedNCT03837509Phase 1/2Results posted
• Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple MyelomaActive, not recruitingNCT03710603Phase 3Results posted
• Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's MacroglobulinemiaTerminatedNCT03679624Phase 2Results posted
• A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial TherapyCompletedNCT03652064Phase 3Results posted
• Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell TransplantTerminatedNCT03622775Phase 2Results posted
• Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell TransplantTerminatedNCT03537599Phase 1/2Results posted
• Short Course Daratumumab in Patients With Multiple MyelomaCompletedNCT03490344Phase 2Results posted
• Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMMTerminatedNCT03481556Phase 1/2Results posted
• Daratumumab in Treating Transplant-Eligible Patients With Multiple MyelomaCompletedNCT03477539Phase 2Results posted
• Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal ImpairmentCompletedNCT03450057Phase 2Results posted
• A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)CompletedNCT03439293Phase 2Results posted
• A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT03357952Phase 2/3Results posted
• A Study of Daratumumab in Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT03290950Phase 2Results posted
• A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT03277105Phase 3Results posted
• Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple MyelomaActive, not recruitingNCT03236428Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) AmyloidosisCompletedNCT03201965Phase 3Results posted
• A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström MacroglobulinemiaCompletedNCT03187262Phase 2Results posted
• Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/DexCompletedNCT03180736Phase 3Results posted
• Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.CompletedNCT03158688Phase 3Results posted
• A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have SpreadCompletedNCT03098550Phase 1/2Results posted
• Daratumumab in Treatment of PGNMID and C3 GNCompletedNCT03095118Phase 2Results posted
• Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeTerminatedNCT03067571Phase 2Results posted
• A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung CancerCompletedNCT03023423Phase 1/2Results posted
• Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT03012880Phase 2Results posted
• Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) TreatmentCompletedNCT03011034Phase 2Results posted
• A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)CompletedNCT03000452Phase 2Results posted
• A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple MyelomaCompletedNCT02951819Phase 2Results posted
• Daratumumab in Treating Patients With Multiple MyelomaCompletedNCT02944565Phase 2Results posted
• A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal TypeCompletedNCT02927925Phase 2Results posted
• Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple MyelomaCompletedNCT02874742Phase 2Results posted

← Daratumumab overview